Key Takeaways
- Novartis’ remibrutinib has shown promising results in clinical trials for relapsing multiple sclerosis (MS), significantly reducing relapse rates compared to teriflunomide.
- The drug has already been approved for chronic spontaneous urticaria, marking its first use beyond oncology.
- Concerns about liver toxicity in BTK inhibitors persist, but Novartis reported no safety issues in the REMODEL trials.
Clinical Trial Success
Novartis’ remibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is making strides in treating relapsing multiple sclerosis (MS). The REMODEL-1 and REMODEL-2 trials, involving around 2,000 adults, demonstrated that remibrutinib significantly reduces annualized relapse rates compared to teriflunomide, a well-established oral therapy.
Both studies met their primary endpoint, showing not only a reduction in relapse rates but also improvements on important secondary endpoints, including a decrease in inflammatory brain lesions. A pooled analysis hinted at potential benefits regarding confirmed disability progression, although details on the magnitude of these effects and safety data are yet to be released. Full results are anticipated to be discussed at MSToronto2026 later this year.
Mechanism of Action
BTK plays a critical role in the signaling pathways of B cells and innate immune cells. By inhibiting BTK, remibrutinib may regulate aspects of the immune response without fully depleting B cells, unlike some existing treatments such as Roche’s Ocrevus. This mechanism extends BTK’s potential to various autoimmune conditions, including MS, lupus, and urticaria.
Remibrutinib has already carved its niche outside of MS, with approval in the U.S. and EU for chronic spontaneous urticaria, becoming the first oral BTK inhibitor licensed for this use.
Challenges in MS Treatment
The landscape for BTK inhibitors in MS has been challenging, with previous drugs like evobrutinib and tolebrutinib failing to outperform teriflunomide in pivotal trials. Despite these setbacks, Roche’s fenebrutinib demonstrated positive results in reducing relapse rates in recent studies, suggesting a gradual return of confidence in BTK therapies.
Liver toxicity has been a critical concern in the development of BTK inhibitors, particularly in MS treatments. However, Novartis has emphasized that the REMODEL trials did not indicate liver safety issues, a significant point for the candidate’s future.
Future Plans
Looking ahead, Novartis plans to submit regulatory applications for remibrutinib focusing on relapsing MS, following the unveiling of detailed trial data. The company is also exploring its application in secondary progressive MS and other immune-mediated conditions, such as hidradenitis suppurativa and food allergies. This development could enhance the treatment landscape for autoimmune diseases.
The content above is a summary. For more details, see the source article.